Remedium Bio announces the publication of preclinical data demonstrating the performance of its adjustable dose gene therapy platform – Prometheus™
Posted:
Prometheus™ was specifically designed as a subcutaneously injected gene delivery system, utilizing the same route of administration as most current therapeutic biologics. Remedium is applying the Prometheus™ platform technology to the development of its lead candidate RMD1202, a single injection disease-modifying treatment for type 2 diabetes and obesity.
Schizophrenia is a psychiatric disorder characterized by altered thinking and emotional patterns, hallucinations, false or irrational beliefs (i.e., delusions), cognitive deficits, and disorganized speech.
Bipolar disorder BD, on the other hand, is marked by extreme mood swings, ranging between periods of…
New joint research program combines UCSF’s advanced clinical and research teams with GE HealthCare’s technical and engineering expertise to develop solutions that directly impact patient care.
Read full article here.
Attendees
Sponsors and Exhibitors
Contact us